Skip to main content

Torley Helen's Form 4 filing

Halozyme Therapeutics, Inc. (HALO) · filed Sep 11, 2026

Accession no.
0001159036-26-000119
Filed
Sep 11, 2026, 8:35 PM ET
Trade date
Sep 9-11, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 10 non-derivative transactions and 3 derivative transactions. Open-market sales total $6.44M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Torley HelenCIK 0001528185Director, Officer (PRESIDENT AND CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 9, 2026Common StockMOption exerciseAcquired+20,000$18.41+$368,200787,780Direct
Sep 9, 2026Common StockSSaleDisposed−13,304$107.22F2−$1,426,481.49774,476Direct
Sep 9, 2026Common StockSSaleDisposed−6,596$107.82F3−$711,187.32767,880Direct
Sep 9, 2026Common StockSSaleDisposed−100$108.67−$10,867767,780Direct
Sep 10, 2026Common StockMOption exerciseAcquired+20,000$18.41+$368,200787,780Direct
Sep 10, 2026Common StockSSaleDisposed−14,588$107.01F4−$1,561,091.06773,192Direct
Sep 10, 2026Common StockSSaleDisposed−5,412$107.58F5−$582,228.37767,780Direct
Sep 11, 2026Common StockMOption exerciseAcquired+20,000$18.41+$368,200787,780Direct
Sep 11, 2026Common StockSSaleDisposed−15,492$107.15F6−$1,660,029.77772,288Direct
Sep 11, 2026Common StockSSaleDisposed−4,508$107.55F7−$484,826.38767,780Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 9, 2026Common StockMOption exerciseDisposed−20,000$18.41−$368,200121,552Direct
Sep 10, 2026Common StockMOption exerciseDisposed−20,000$18.41−$368,200101,552Direct
Sep 11, 2026Common StockMOption exerciseDisposed−20,000$18.41−$368,20081,552Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.640 to $107.632. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F3

Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.640 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F4

Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.360 to $107.350 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range

Referenced by the price of 1 transaction in Table I.

F5

Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.360 to $107.820 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range

Referenced by the price of 1 transaction in Table I.

F6

Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.400 to $107.390. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F7

Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.400 to $107.960. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)